BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/18/2019 3:14:49 AM | Browse: 962 | Download: 1754
 |
Received |
|
2018-10-05 07:51 |
|
Peer-Review Started |
|
2018-10-06 00:18 |
|
To Make the First Decision |
|
2018-11-16 01:44 |
|
Return for Revision |
|
2018-11-21 03:18 |
|
Revised |
|
2018-12-14 18:41 |
|
Second Decision |
|
2018-12-29 03:19 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-12-30 02:47 |
|
Articles in Press |
|
2018-12-30 02:47 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-01-22 18:15 |
|
Typeset the Manuscript |
|
2019-02-11 06:29 |
|
Publish the Manuscript Online |
|
2019-02-18 03:14 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Systematic Reviews |
| Article Title |
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Henith Raj, Harsh Durgia, Rajan Palui, Sadishkumar Kamalanathan, Sandhiya Selvarajan, Sitanshu Sekhar Kar and Jayaprakash Sahoo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jayaprakash Sahoo, MD, Associate Professor, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Room No. 5444, the 4th Floor, Superspeciality block, Pondicherry 605006, India. jayaprakash.s@jipmer.edu.in |
| Key Words |
Alanine aminotransferase; Hepatic fat; Hepatic fibrosis; Non-alcoholic fatty liver disease; Sodium-glucose cotransporter-2 inhibitor; Type 2 diabetes mellitus |
| Core Tip |
The frequent coexistence of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes, their adverse health consequences, and lack of adequate therapeutic options makes it necessary to search for newer alternatives. Currently, pioglitazone and vitamin E are recommended in addition to lifestyle modifications for the management of NAFLD. Animal studies have shown that sodium glucose cotransporter-2 inhibitors might be beneficial in NAFLD present in diabetes patients. The current systematic review shows that sodium glucose cotransporter-2 inhibitors improve the serum level of liver enzymes, liver fat, and liver fibrosis with additional beneficial effects on various metabolic parameters in type 2 diabetes patients with NAFLD. |
| Publish Date |
2019-02-18 03:14 |
| Citation |
Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132 |
| URL |
https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v10.i2.114 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
